The Cooper Cos. (NYSE:COO)‘s stock had its “overweight” rating reissued by investment analysts at Piper Jaffray Cos. in a report issued on Tuesday. They currently have a $185.00 price objective on the medical device company’s stock. Piper Jaffray Cos.’s target price suggests a potential upside of 3.28% from the stock’s current price.
A number of hedge funds have made changes to their positions in the stock. Private Trust Co. NA increased its stake in shares of The Cooper Cos. by 1.1% in the second quarter. Private Trust Co. NA now owns 2,898 shares of the medical device company’s stock valued at $497,000 after buying an additional 32 shares during the last quarter. Profit Investment Management LLC increased its stake in shares of The Cooper Cos. by 1.5% in the second quarter. Profit Investment Management LLC now owns 3,291 shares of the medical device company’s stock valued at $565,000 after buying an additional 50 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of The Cooper Cos. by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,095 shares of the medical device company’s stock valued at $1,892,000 after buying an additional 68 shares during the last quarter. Legacy Private Trust Co. increased its stake in shares of The Cooper Cos. by 2.1% in the second quarter. Legacy Private Trust Co. now owns 3,365 shares of the medical device company’s stock valued at $577,000 after buying an additional 70 shares during the last quarter. Finally, Diversified Trust Co increased its stake in shares of The Cooper Cos. by 5.9% in the second quarter. Diversified Trust Co now owns 1,800 shares of the medical device company’s stock valued at $309,000 after buying an additional 100 shares during the last quarter.
A number of other brokerages have also issued reports on COO. Stifel Nicolaus boosted their target price on The Cooper Cos. from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, June 30th. JPMorgan Chase & Co. started coverage on The Cooper Cos. in a research report on Wednesday, July 13th. They set a “buy” rating on the stock. Cleveland Research raised The Cooper Cos. from a “neutral” rating to a “buy” rating in a research report on Monday, May 16th. Wells Fargo & Co. reissued a “hold” rating on shares of The Cooper Cos. in a research report on Friday, June 3rd. Finally, Jefferies Group raised The Cooper Cos. from a “hold” rating to a “buy” rating and set a $175.00 price target on the stock in a research report on Friday, April 15th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $167.00.
The Cooper Cos. (NYSE:COO) last announced its quarterly earnings data on Thursday, June 2nd. The medical device company reported $2.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.91 by $0.14. During the same period last year, the business posted $1.72 EPS. The firm earned $484.80 million during the quarter. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, equities analysts forecast that The Cooper Cos. will post $8.40 EPS for the current fiscal year.
The business also recently declared a semiannual dividend, which will be paid on Friday, August 5th. Stockholders of record on Friday, July 22nd will be paid a dividend of $0.03 per share. The ex-dividend date of this dividend is Wednesday, July 20th. This represents a dividend yield of 0.03%.
In other news, Director A Thomas Bender sold 4,000 shares of the company’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $164.19, for a total transaction of $656,760.00. Following the completion of the sale, the director now owns 14,978 shares in the company, valued at approximately $2,459,237.82. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Stanley Md Zinberg sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 29th. The stock was sold at an average price of $170.00, for a total value of $1,700,000.00. Following the sale, the director now owns 899 shares of the company’s stock, valued at approximately $152,830. The disclosure for this sale can be found here.
The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.
